Dabigatran prevents CV events in A-fib patients

01/3/2013 | Healio

The anticoagulant dabigatran performed safely and effectively in a group of 938 unselected patients with atrial fibrillation, according to a German study presented at a meeting. Less than 2% of the patients experienced major cardiovascular events, and 1% experienced minor cardiovascular events. Bleeding complications were experienced by 14.9% of patients, but only 1.5% faced major bleeding, the study found.

View Full Article in:

Healio

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX